查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1657674

全球呼吸診斷市場（至 2030 年）按產品/服務細分（設備與裝置）、測試類型（機械測試、OSA 測試、影像檢查、分子測試）、疾病（結核病、慢性阻塞性肺病、肺癌）和診斷類型（症候群、病因、預後）分類

Respiratory Diagnostics Market by Product & Services (Instrument & Devices), Test type (Mechanical, OSA, Imaging, Molecular Test), Disease (Tuberculosis, COPD, Lung Cancer ) and Diagnosis Type(Syndromic, Aetiological, Prognosis)-Global Forecast to 2030
出版日期: | 出版商: MarketsandMarkets | 英文 404 Pages | 商品交期: 最快1-2個工作天內

價格

呼吸診斷市場規模預計將從 2024 年的 61.7 億美元增加到 2030 年的 90.2 億美元，預測期內的複合年成長率為 6.5%。

分子診斷和先進影像解決方案等診斷領域的創新也提高了氣喘、結核病和肺癌等疾病的檢測準確性和速度。醫療保健提供者和患者對早期診斷益處的認知不斷提高，以及政府資助的健康分析計畫增加也推進因素了對呼吸診斷解決方案的需求。 COVID-19 大流行表明，在治療呼吸道感染疾病方面需要有效、可靠的診斷方法。然而，有關新產品核准、標籤要求和完全遵守品質標準的法規結構的最新變化等多種因素正在抑制市場的成長。

研究範圍
調查年份 2022-2030
基準年 2023
預測期 2024-2030
單元 金額（美元）
部分 產品與服務、檢測類型、疾病、診斷類型
目標區域 北美、歐洲、亞太地區、中東和非洲、拉丁美洲

“按產品/服務類別分類，設備/器材部門佔有最大佔有率。”

影像設備、肺計量計和其他呼吸診斷設備等診斷技術的進步正在提升該產業的重要性。此外，全球呼吸系統疾病的發生率不斷上升，對先進、準確的診斷工具的需求也大大增加。先進的就地檢驗設備和可攜式診斷機等創新技術使醫療專業人員能夠快速且準確地進行呼吸評估，從而推動設備和器械領域的成長。

“按檢查類型分類，機械檢查部分佔有最大的佔有率。”

機械測試，包括肺計量計和峰值流量計等工具，對於評估肺功能和氣流至關重要。氣喘和慢性阻塞性肺病等慢性呼吸系統疾病的盛行率不斷上升，大大增加了對這些診斷方法的依賴。數位肺量計和攜帶式設備等技術的進步提高了機械測試的準確性、易用性和可訪問性，從而導致其在臨床和家庭環境中廣泛應用。此外，越來越重視早期診斷和持續監測呼吸系統健康，特別是在慢性病的管理中，也是推動呼吸診斷市場這一領域擴張的主要因素。

“預計北美將在預測期內實現最快的複合年成長率”

在各地區中，北美預計將佔據主導地位，並在 2023 年佔據最大佔有率。這一主導地位得益於高度發展的醫療保健體系、高發生率的呼吸系統疾病以及對醫療保健創新的大量投入。先進的診斷技術注重準確和快速的檢測，這推動了所有參數的趨勢，包括醫療成本的上漲、人口老化以及呼吸系統疾病導致的公共衛生挑戰。總體法律規範鼓勵採用這些診斷解決方案來實現持續成長。

本報告調查了全球呼吸診斷市場，並提供了市場概況、影響市場成長的各種因素分析、技術和專利趨勢、法律制度、案例研究、市場規模趨勢和預測、各個細分市場、地區/主要國家的詳細分析、競爭格局和主要企業的概況。

目錄

第 1 章 簡介

第2章調查方法

第3章執行摘要

第 4 章重要考察

第5章 市場概況

  • 市場動態
    • 驅動程式
    • 限制因素
    • 機會
    • 任務
  • 產業趨勢
  • 技術分析
  • 波特五力分析
  • 監管分析
  • 專利分析
  • 貿易分析
  • 定價分析
  • 價值鏈分析
  • 主要相關利益者和採購標準
  • 重要會議及活動
  • 未滿足的需求/最終用戶期望
  • 鄰近市場分析
  • 生態系分析
  • 案例研究分析
  • 供應鏈分析
  • 影響我們客戶業務的趨勢/中斷
  • 投資金籌措場景
  • 退款情形
  • 人工智慧/生成式人工智慧對呼吸診斷市場的影響

6. 呼吸診斷市場（按產品和服務細分）

  • 設備和裝置
  • 檢測方法和試劑
  • 服務和軟體

7. 呼吸診斷市場（依測試類型）

  • 機械檢查
    • 肺功能檢查
    • 阻塞型睡眠呼吸中止症的診斷檢查
    • 其他
  • 影像檢查
    • X光
    • 電腦斷層掃描
    • 磁振造影（MRI）
    • 正子斷層掃描 (PET)
    • 其他
  • 常規診斷測試
    • 免疫診斷
    • 生物化學檢驗
    • 顯微鏡
  • 分子診斷檢測
    • 聚合酵素鏈鎖反應（PCR）
    • 核酸增幅檢查（NAAT）
    • 原位雜合反應（ISH）
    • DNA定序與次世代定序(NGS)
    • 微陣列
    • 其他

第 8 章呼吸診斷市場（按疾病）

  • 結核
  • 氣喘
  • 肺癌
    • 非小細胞肺癌（NSCLC）
    • 小細胞肺癌 (SCLC)
    • 其他
  • 慢性阻塞性肺病(COPD)
  • 肺炎
  • 其他

9. 呼吸診斷市場（依診斷類型）

  • 症候群診斷
  • 病因診斷
  • 預後診斷

第 10 章呼吸診斷市場（依最終用戶）

  • 醫院和診所
  • 診斷實驗室
  • 長期照護和專科中心
  • 學術研究所

第 11 章呼吸診斷市場（按地區）

  • 北美洲
    • 宏觀經濟展望
    • 美國
    • 加拿大
  • 歐洲
    • 宏觀經濟展望
    • 德國
    • 英國
    • 法國
    • 義大利
    • 西班牙
    • 其他
  • 亞太地區
    • 宏觀經濟展望
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 韓國
    • 其他
  • 拉丁美洲
    • 宏觀經濟展望
    • 巴西
    • 墨西哥
    • 其他
  • 中東和非洲
    • 宏觀經濟展望
    • 海灣合作理事會國家
    • 其他

第12章 競爭格局

  • 主要參與企業的策略/優勢
  • 收益分析
  • 市場佔有率分析
  • 企業評估矩陣：主要企業
  • 公司估值矩陣：Start-Ups/小型企業
  • 品牌/產品比較
  • 主要企業研發支出
  • 估值及財務指標
  • 競爭場景

第13章 公司簡介

  • 主要企業
    • KONINKLIJKE PHILIPS NV
    • BECTON, DICKINSON AND COMPANY
    • ABBOTT LABORATORIES
    • THERMO FISHER SCIENTIFIC INC.
    • GE HEALTHCARE TECHNOLOGIES, INC.
    • BIO-RAD LABORATORIES, INC.
    • BIOMERIEUX
    • REVVITY, INC.
    • SEEGENE INC.
    • NIHON KOHDEN CORPORATION
    • VITALOGRAPH
    • SDI DIAGNOSTICS
    • RESMED INC.
    • SIEMENS HEALTHINEERS AG
    • COSMED SRL
    • HOLOGIC, INC.
    • QIAGEN NV
  • 其他公司
    • MGC DIAGNOSTICS CORPORATION
    • VISBY MEDICAL, INC.
    • BRIOTA TECHNOLOGIES PVT. LTD.
    • BIRD HEALTHCARE
    • LOWENSTEIN MEDICAL SE & CO. KG
    • PROAXSIS
    • NDD MEDICAL TECHNOLOGIES
    • COMPUMEDICS LIMITED

第14章 附錄

Product Code: MD 4740

The global respiratory diagnostics market is projected to reach USD 9.02 billion by 2030 from USD 6.17 billion in 2024, at a CAGR of 6.5% during the forecast period. The respiratory diagnostics market is driven by many rising impacts with respect to improving cases of respiratory diseases around the world. Innovative technologies in diagnosis, such as molecular diagnostics and advanced imaging solutions, have also improved the accuracy and speed of detection for conditions such as asthma, tuberculosis, or lung cancers. Increased awareness for healthcare providers and patients about the benefits of early diagnosis and more government-sponsored, healthy analysis programs have also served as important fuel sources in the demand for respiratory diagnostic solutions. The COVID-19 pandemic has demonstrated the need for efficient and reliable diagnostics in the management of respiratory infections. However, the market growth is restricted by several factors, including the recent changes in the regulatory framework concerning the approval of new products, their labeling requirements, and complete conformance to quality standards.

Scope of the Report
Years Considered for the Study2022-2030
Base Year2023
Forecast Period2024-2030
Units ConsideredValue (USD)
SegmentsProduct & Services, Test type, Disease and Diagnosis Type,
Regions coveredNorth America, Europe, Asia Pacific, Middle East & Africa, Latin America

"Instruments and Devices segment accounted for the largest share in the respiratory diagnostics market."

The growing advancements in diagnosis technologies such as diagnostic imaging devices, spirometers, and other respiratory diagnostic instruments have led to such importance in this segment. In addition to this, the rising prevalence of respiratory disease across the globe has greatly increased the demand for advanced and accurate diagnostics tools. The innovations in point-of-care testing devices and portable diagnostic instruments, such as advanced point-of-care testing instruments and portable diagnostic instruments, have enhanced the growth of the Instrument and Devices segment, allowing rapid and accurate respiratory assessment by health professionals. Hence, the above factors are driving respiratory diagnostics market growth in the region.

"The Mechanical tests segment accounted for the largest share in the respiratory diagnostics market."

Mechanical tests, including tools like spirometers and peak flow meters, are essential for assessing lung function and airflow. The rising incidence of chronic respiratory conditions, such as asthma and COPD, has significantly increased the reliance on these diagnostic methods. Enhanced technological innovations, such as digital spirometry and portable devices, have improved the accuracy, ease of use, and accessibility of mechanical tests, making them more widely adopted in clinical and home settings. Furthermore, the growing emphasis on early diagnosis and continuous monitoring of respiratory health, particularly in managing chronic diseases, is a major driver for the expansion of this segment within the respiratory diagnostics market.

"Asthma segment accounted for the largest share in the global respiratory diagnostics market."

Increase accession of environmental pollutants, changing lifestyles, and genetic factors contributing to increasing cases in asthma which further necessitates the requirement of advanced diagnostic solutions. Asthma is one of the segments that include diagnostic modalities, pulmonary function tests, imaging techniques, and biomarker assessments, all of which comprise an option for asthma diagnosis and management. However, ongoing research and development initiatives focusing on personalized medicine drive the segment for respiratory diagnostics.

"Syndromic segment has accounted for the largest share in the global respiratory diagnostics market."

Syndromic segment holds the largest share in the respiratory diagnostics market due to its capabilities of rapid and widespread diagnosis for many pathogens from a single test. The efficiency is very important since in the management of conditions such as influenza and pneumonia, it is vital timeously to identify the causative agent for its effective treatment. Syndromic panels reduce the time in diagnosis and keep for diagnosis, as this promotes early interventions. At the same time, the applications of techniques such as PCR and multiplex assays have improved specificity and access to syndromic panels. Increasing need drives point-of-care testing in hospitals and clinics into adopting syndromic diagnostic solutions.

"Hospitals and clinics end-user segment held the largest market share growing at the highest CAGR during the forecast period of the global respiratory diagnostics market."

While respiratory diseases proliferate, there has been an surged awareness about the need for their early detection. This has in turn led to an increase in the diagnostic procedures carried out in most of these facilities. The segment Hospitals and Clinics cater to a wide range of diagnostic equipment and services such as imaging studies, pulmonary function tests, and molecular diagnostics; hence it offers a complete solution for respiratory health assessment. As a result, the segment positioning in this whole input-output course of illness diagnosis, management, and therapy clearly puts hospitals and clinics within this input-output chain addressing the emerging demand for respiratory diagnostics in many healthcare institutions.

"North America to witness the fastest CAGR in the respiratory diagnostics market during the forecast period."

Respiratory diagnostics market has been segmented into five major regional segments: North America, Europe, Asia Pacific, Latin America and Middle East and Africa. In 2023, North America is expected to be in the leading position, holding the largest share of the global respiratory diagnostic market. This leadership position had been fueled by a highly developed healthcare system, along with high prevalence rates of respiratory diseases and considerable expenditure toward innovation in healthcare. According to their advanced diagnostic technologies, the focus is toward accurate and rapid testing; hence, they tend to give all of the parameters, including increased healthcare spending, larger aging populations, and strong emphasis on public health initiatives that are caused by respiratory issues, for example. Their overall regulatory framework encourages the adoption of these diagnostic solutions for continued growth.

Breakdown of supply-side primary interviews: * By Company Type: Tier 1 - 35%, Tier 2 - 40%, and Tier 3 - 25% * By Designation: C-level - 30%, Director-level - 23%, and Others - 47% * By Region: North America - 25%, Europe - 35%, APAC - 20%, Latin America - 13%, Middle East & Africa - 7%

Breakdown of demand-side primary interviews: * By Company Type: Hospitals & Clinics - 62%, Diagnostics Laboratories - 16%, and Other End Users - 22% * By Designation: Senior Managers - 35%, Chief Officers - 28%, Radiologists - 25% and Other Designations - 12% * By Region: North America - 32%, Europe - 25%, APAC - 20%, Latin America - 14%, Middle East & Africa - 9%

Research Coverage

This report studies respiratory diagnostics market based on products and services, test type, disease indication, end user, and region. The report also studies factors (such as drivers, restraints, opportunities, and challenges) affecting market growth. It analyzes the opportunities and challenges in the market and provides details of the competitive landscape for market leaders. Furthermore, the report analyzes micro markets with respect to their individual growth trends and forecasts the revenue of the market segments with respect to five main regions and respective countries.

Reasons to Buy the Report

The report can help established firms as well as new entrants/smaller firms to gauge the pulse of the market, which, in turn, would help them garner a greater share. Firms purchasing the report could use one or a combination of the below-mentioned five strategies.

This report provides insights into the following pointers:

  • Analysis of key drivers (increasing incidences of respiratory disorders, growing aging population and changing lifestyle, growing awareness about respiratory health, advancements in diagnostic technologies), restraints (high cost of diagnostic tests, limited reimbursement coverage, and lack of skilled professionals for advanced diagnostics), opportunities (increasing healthcare infrastructure and rising disposable incomes in emerging economies, rising demand for Point-of-care (POC) testing, and growing awareness of untreated sleep apnea), and challenges (complexity in diagnosing viral respiratory infections, and limited access to peripheral lung lesions in bronchoscopy) influencing the growth of respiratory diagnostics market.
  • Product Development/Innovation: Detailed insights on upcoming technologies, research and development activities, and product launches in respiratory diagnostics market.
  • Market Development: Comprehensive information about lucrative emerging markets. The report analyzes the markets for various types of respiratory diagnostics across regions.
  • Market Diversification: Exhaustive information about products, untapped regions, recent developments, and investments in respiratory diagnostics market.
  • Competitive Assessment: In-depth assessment of market shares, strategies, products, distribution networks, and manufacturing capabilities of the leading players in respiratory diagnostics market.

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 STUDY OBJECTIVES
  • 1.2 MARKET DEFINITION
  • 1.3 MARKET SCOPE
    • 1.3.1 MARKETS & REGIONS COVERED
    • 1.3.2 INCLUSIONS & EXCLUSIONS
    • 1.3.3 YEARS CONSIDERED
    • 1.3.4 CURRENCY CONSIDERED
  • 1.4 STAKEHOLDERS
  • 1.5 SUMMARY OF CHANGES

2 RESEARCH METHODOLOGY

  • 2.1 RESEARCH DATA
    • 2.1.1 SECONDARY DATA
      • 2.1.1.1 Key data from secondary sources
    • 2.1.2 PRIMARY DATA
      • 2.1.2.1 Primary research objectives
      • 2.1.2.2 Key data from primary sources
      • 2.1.2.3 Key industry insights
      • 2.1.2.4 Breakdown of primary interviews
  • 2.2 MARKET SIZE ESTIMATION
    • 2.2.1 SUPPLY-SIDE ANALYSIS (REVENUE SHARE ANALYSIS)
    • 2.2.2 COMPANY PRESENTATIONS AND PRIMARY INTERVIEWS
    • 2.2.3 TOP-DOWN APPROACH: SUPPLY-SIDE ANALYSIS
  • 2.3 DATA TRIANGULATION AND MARKET BREAKDOWN
  • 2.4 MARKET SHARE ESTIMATION
  • 2.5 STUDY ASSUMPTIONS
  • 2.6 RESEARCH LIMITATIONS
    • 2.6.1 METHODOLOGY-RELATED LIMITATIONS
    • 2.6.2 SCOPE-RELATED LIMITATIONS
  • 2.7 RISK ASSESSMENT

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

  • 4.1 RESPIRATORY DIAGNOSTICS MARKET OVERVIEW
  • 4.2 ASIA PACIFIC: RESPIRATORY DIAGNOSTICS MARKET, BY PRODUCT & SERVICE AND COUNTRY (2023)
  • 4.3 RESPIRATORY DIAGNOSTICS MARKET: REGIONAL MIX
  • 4.4 RESPIRATORY DIAGNOSTICS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES

5 MARKET OVERVIEW

  • 5.1 INTRODUCTION
  • 5.2 MARKET DYNAMICS
    • 5.2.1 DRIVERS
      • 5.2.1.1 Increasing incidence of respiratory disorders
      • 5.2.1.2 Expanding geriatric population and rise in sedentary lifestyles
      • 5.2.1.3 Growing awareness about respiratory health
      • 5.2.1.4 Advancements in diagnostic technologies
    • 5.2.2 RESTRAINTS
      • 5.2.2.1 High cost of diagnostic tests
      • 5.2.2.2 Limited reimbursements
      • 5.2.2.3 Shortage of skilled professionals
    • 5.2.3 OPPORTUNITIES
      • 5.2.3.1 High growth potential of emerging economies
      • 5.2.3.2 Increasing demand for POC testing
      • 5.2.3.3 Growing awareness about untreated OSA
    • 5.2.4 CHALLENGES
      • 5.2.4.1 Complexities associated with diagnosis of viral respiratory infections
      • 5.2.4.2 Limited access to peripheral lung lesions in bronchoscopy
  • 5.3 INDUSTRY TRENDS
    • 5.3.1 POINT-OF-CARE TESTING
    • 5.3.2 PERSONALIZED MEDICINE
  • 5.4 TECHNOLOGY ANALYSIS
    • 5.4.1 KEY TECHNOLOGIES
      • 5.4.1.1 Home-based & personal DHTs
      • 5.4.1.2 PFT tools and molecular & imaging diagnostics
    • 5.4.2 COMPLEMENTARY TECHNOLOGIES
      • 5.4.2.1 AI-enhanced imaging
      • 5.4.2.2 Serological & telehealth platforms
    • 5.4.3 ADJACENT TECHNOLOGIES
      • 5.4.3.1 Rapid respiratory diagnostic tests
  • 5.5 PORTER'S FIVE FORCES ANALYSIS
    • 5.5.1 THREAT OF NEW ENTRANTS
    • 5.5.2 THREAT OF SUBSTITUTES
    • 5.5.3 BARGAINING POWER OF SUPPLIERS
    • 5.5.4 BARGAINING POWER OF BUYERS
    • 5.5.5 INTENSITY OF COMPETITIVE RIVALRY
  • 5.6 REGULATORY ANALYSIS
    • 5.6.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
    • 5.6.2 REGULATORY LANDSCAPE
      • 5.6.2.1 North America
        • 5.6.2.1.1 US
        • 5.6.2.1.2 Canada
      • 5.6.2.2 Europe
      • 5.6.2.3 Asia Pacific
        • 5.6.2.3.1 India
        • 5.6.2.3.2 China
        • 5.6.2.3.3 Japan
      • 5.6.2.4 Latin America
      • 5.6.2.5 Middle East & Africa
  • 5.7 PATENT ANALYSIS
    • 5.7.1 KEY PATENTS GRANTED
  • 5.8 TRADE ANALYSIS
    • 5.8.1 IMPORT DATA FOR HS CODE 901819
    • 5.8.2 EXPORT DATA FOR HS CODE 901819
  • 5.9 PRICING ANALYSIS
    • 5.9.1 AVERAGE SELLING PRICE OF RESPIRATORY DIAGNOSTIC PRODUCTS, BY KEY PLAYER (2024)
    • 5.9.2 AVERAGE SELLING PRICE TREND OF RESPIRATORY DIAGNOSTIC PRODUCTS, BY REGION, 2021-2023
  • 5.10 VALUE CHAIN ANALYSIS
  • 5.11 KEY STAKEHOLDERS & BUYING CRITERIA
    • 5.11.1 KEY STAKEHOLDERS IN BUYING PROCESS
    • 5.11.2 KEY BUYING CRITERIA
  • 5.12 KEY CONFERENCES & EVENTS, 2024-2025
  • 5.13 UNMET NEEDS/END-USER EXPECTATIONS
  • 5.14 ADJACENT MARKET ANALYSIS
  • 5.15 ECOSYSTEM ANALYSIS
  • 5.16 CASE STUDY ANALYSIS
  • 5.17 SUPPLY CHAIN ANALYSIS
  • 5.18 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS' BUSINESSES
  • 5.19 INVESTMENT & FUNDING SCENARIO
  • 5.20 REIMBURSEMENT SCENARIO
  • 5.21 IMPACT OF AI/GENERATIVE AI ON RESPIRATORY DIAGNOSTICS MARKET

6 RESPIRATORY DIAGNOSTICS MARKET, BY PRODUCT & SERVICE

  • 6.1 INTRODUCTION
  • 6.2 INSTRUMENTS & DEVICES
    • 6.2.1 INTRODUCTION OF AUTOMATED & HIGH-THROUGHPUT INSTRUMENTS TO DRIVE MARKET
  • 6.3 ASSAYS & REAGENTS
    • 6.3.1 INCREASING DEMAND FOR RESPIRATORY DIAGNOSTIC TEST KITS TO PROPEL MARKET
  • 6.4 SERVICES & SOFTWARE
    • 6.4.1 INCREASING DEMAND FOR CONSISTENT UPGRADES AND SUPPORT SERVICES TO FUEL MARKET

7 RESPIRATORY DIAGNOSTICS MARKET, BY TEST TYPE

  • 7.1 INTRODUCTION
  • 7.2 MECHANICAL TESTS
    • 7.2.1 PULMONARY FUNCTION TESTS
      • 7.2.1.1 Spirometry
        • 7.2.1.1.1 Diagnosis of COPD and pulmonary fibrosis to drive market
      • 7.2.1.2 Peak flow tests
        • 7.2.1.2.1 Ability to provide accurate lung function monitoring with non-invasiveness benefits to fuel uptake
      • 7.2.1.3 Other pulmonary function tests
    • 7.2.2 OBSTRUCTIVE SLEEP APNEA DIAGNOSTIC TESTS
      • 7.2.2.1 Large presence of untreated population to drive market
    • 7.2.3 OTHER MECHANICAL TESTS
  • 7.3 IMAGING TESTS
    • 7.3.1 X-RAY
      • 7.3.1.1 Integration of AI into X-ray devices for enhanced imaging capabilities to drive market
    • 7.3.2 COMPUTED TOMOGRAPHY
      • 7.3.2.1 Rising focus on obtaining high-resolution CT images to boost demand
    • 7.3.3 MAGNETIC RESONANCE IMAGING (MRI)
      • 7.3.3.1 Ability to provide detailed lung images without radiation exposure to drive market
    • 7.3.4 POSITRON EMISSION TOMOGRAPHY (PET)
      • 7.3.4.1 Growing focus on detection & monitoring of treatment response to lung cancer to drive market
    • 7.3.5 OTHER IMAGING TESTS
  • 7.4 TRADITIONAL DIAGNOSTIC TESTS
    • 7.4.1 IMMUNODIAGNOSTICS
      • 7.4.1.1 Rising demand for rapid disease diagnosis to fuel uptake
    • 7.4.2 BIOCHEMICAL TESTS
      • 7.4.2.1 Ability to accurately measure biomarkers in pneumonia and bronchitis infections to boost demand
    • 7.4.3 MICROSCOPY
      • 7.4.3.1 Inadequate sensitivity towards emerging viruses to restrain market
  • 7.5 MOLECULAR DIAGNOSTIC TESTS
    • 7.5.1 POLYMERASE CHAIN REACTION (PCR)
      • 7.5.1.1 Development of portable and real-time PCR machines to drive market
    • 7.5.2 NUCLEIC ACID AMPLIFICATION TEST (NAAT)
      • 7.5.2.1 Rapid identification of viral, bacterial, and fungal infections to fuel demand
    • 7.5.3 IN SITU HYBRIDIZATION (ISH)
      • 7.5.3.1 Utilization of probes for pathogen detection to support market growth
    • 7.5.4 DNA SEQUENCING & NEXT-GENERATION SEQUENCING (NGS)
      • 7.5.4.1 High-throughput capabilities for rapid analysis of genetic data to propel market
    • 7.5.5 MICROARRAYS
      • 7.5.5.1 Detection of hepatitis C and respiratory viruses to support market growth
    • 7.5.6 OTHER MOLECULAR DIAGNOSTIC TESTS

8 RESPIRATORY DIAGNOSTICS MARKET, BY DISEASE TYPE

  • 8.1 INTRODUCTION
  • 8.2 TUBERCULOSIS
    • 8.2.1 FAVORABLE FUNDING INITIATIVES FOR TB TREATMENT TO DRIVE MARKET
  • 8.3 ASTHMA
    • 8.3.1 INCREASING AIR POLLUTION AND GROWING USE OF TOBACCO-BASED PRODUCTS TO DRIVE MARKET
  • 8.4 LUNG CANCER
    • 8.4.1 NON-SMALL-CELL LUNG CANCER (NSCLC)
      • 8.4.1.1 Rising investments in advanced radiographic technologies to fuel market
    • 8.4.2 SMALL-CELL LUNG CANCER (SCLC)
      • 8.4.2.1 Growing emphasis on precision testing to drive market
    • 8.4.3 OTHER LUNG CANCERS
  • 8.5 CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)
    • 8.5.1 ADVANCEMENTS IN SPIROMETRY AND PLETHYSMOGRAPHY FOR COPD DIAGNOSIS TO FUEL MARKET
  • 8.6 PNEUMONIA
    • 8.6.1 RISING INCIDENCE OF RESPIRATORY INFECTIONS TO BOOST DEMAND
  • 8.7 OTHER DISEASES

9 RESPIRATORY DIAGNOSTICS MARKET, BY DIAGNOSIS TYPE

  • 9.1 INTRODUCTION
  • 9.2 SYNDROMIC DIAGNOSIS
    • 9.2.1 DETECTION OF MULTIPLE PANELS OF VIRAL PATHOGENS TO PROPEL MARKET
  • 9.3 ETIOLOGICAL DIAGNOSIS
    • 9.3.1 IDENTIFICATION OF SPECIFIC CAUSE OF RESPIRATORY ILLNESSES TO FUEL MARKET
  • 9.4 PROGNOSIS DIAGNOSIS
    • 9.4.1 ASSESSMENT OF BIOMARKERS FOR DISEASE PROGRESSION TO SUPPORT MARKET GROWTH

10 RESPIRATORY DIAGNOSTICS MARKET, BY END USER

  • 10.1 INTRODUCTION
  • 10.2 HOSPITALS & CLINICS
    • 10.2.1 GROWING ACCESSIBILITY TO ADVANCED EQUIPMENT TO FUEL MARKET
  • 10.3 DIAGNOSTIC LABORATORIES
    • 10.3.1 ABILITY TO PROVIDE AFFORDABLE TESTING PROCESSES WITH TIMELY RESULTS TO BOOST DEMAND
  • 10.4 LONG-TERM CARE & SPECIALTY CENTERS
    • 10.4.1 PROVISION OF SPECIALIZED & ADVANCED SERVICES TO PROPEL MARKET
  • 10.5 ACADEMIC & RESEARCH INSTITUTES
    • 10.5.1 FAVORABLE FUNDING INITIATIVES TO SUPPORT MARKET GROWTH

11 RESPIRATORY DIAGNOSTICS MARKET, BY REGION

  • 11.1 INTRODUCTION
  • 11.2 NORTH AMERICA
    • 11.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA
    • 11.2.2 US
      • 11.2.2.1 Growing accessibility to technologically advanced products to boost demand
    • 11.2.3 CANADA
      • 11.2.3.1 Rising incidence of COPD to drive market
  • 11.3 EUROPE
    • 11.3.1 MACROECONOMIC OUTLOOK FOR EUROPE
    • 11.3.2 GERMANY
      • 11.3.2.1 Increasing public healthcare expenditure to foster market growth
    • 11.3.3 UK
      • 11.3.3.1 Rising establishment of hospitals and increasing number of surgical procedures to fuel market
    • 11.3.4 FRANCE
      • 11.3.4.1 High prevalence of smoking and increasing demand for respiratory devices to drive market
    • 11.3.5 ITALY
      • 11.3.5.1 Unfavorable amendments to healthcare policies to restrain market
    • 11.3.6 SPAIN
      • 11.3.6.1 Increasing demand for home healthcare services to support market growth
    • 11.3.7 REST OF EUROPE
  • 11.4 ASIA PACIFIC
    • 11.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC
    • 11.4.2 JAPAN
      • 11.4.2.1 Availability of universal healthcare reimbursement policy to drive market
    • 11.4.3 CHINA
      • 11.4.3.1 High incidence of viral respiratory infections to propel market
    • 11.4.4 INDIA
      • 11.4.4.1 Expansion of leading medical device manufacturers and large target patient population to drive market
    • 11.4.5 AUSTRALIA
      • 11.4.5.1 High prevalence of chronic lung diseases to boost demand
    • 11.4.6 SOUTH KOREA
      • 11.4.6.1 Expanding geriatric population and rising incidence of chronic respiratory conditions to fuel market
    • 11.4.7 REST OF ASIA PACIFIC
  • 11.5 LATIN AMERICA
    • 11.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA
    • 11.5.2 BRAZIL
      • 11.5.2.1 Favorable government initiatives for healthcare sector improvement to drive market
    • 11.5.3 MEXICO
      • 11.5.3.1 Rising prevalence of obesity & hypertension to fuel uptake
    • 11.5.4 REST OF LATIN AMERICA
  • 11.6 MIDDLE EAST & AFRICA
    • 11.6.1 MACROECONOMIC OUTLOOK FOR MIDDLE EAST & AFRICA
    • 11.6.2 GCC COUNTRIES
      • 11.6.2.1 Kingdom of Saudi Arabia (KSA)
        • 11.6.2.1.1 Investments in advanced healthcare technologies to drive market
      • 11.6.2.2 United Arab Emirates (UAE)
        • 11.6.2.2.1 Rising prevalence of asthma to support market growth
      • 11.6.2.3 Other GCC Countries
    • 11.6.3 REST OF MIDDLE EAST & AFRICA

12 COMPETITIVE LANDSCAPE

  • 12.1 INTRODUCTION
  • 12.2 KEY PLAYER STRATEGIES/RIGHT TO WIN, JANUARY 2021-DECEMBER 2024
  • 12.3 REVENUE ANALYSIS, 2019-2023
  • 12.4 MARKET SHARE ANALYSIS, 2023
    • 12.4.1 RANKING OF KEY MARKET PLAYERS
  • 12.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2023
    • 12.5.1 STARS
    • 12.5.2 EMERGING LEADERS
    • 12.5.3 PERVASIVE PLAYERS
    • 12.5.4 PARTICIPANTS
    • 12.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2023
      • 12.5.5.1 Company footprint
      • 12.5.5.2 Region footprint
      • 12.5.5.3 Product & service footprint
      • 12.5.5.4 Test type footprint
      • 12.5.5.5 Disease type footprint
      • 12.5.5.6 End-user footprint
  • 12.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2023
    • 12.6.1 PROGRESSIVE COMPANIES
    • 12.6.2 RESPONSIVE COMPANIES
    • 12.6.3 DYNAMIC COMPANIES
    • 12.6.4 STARTING BLOCKS
    • 12.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2023
  • 12.7 BRAND/PRODUCT COMPARISON
  • 12.8 R&D EXPENDITURE OF KEY PLAYERS
  • 12.9 COMPANY VALUATION & FINANCIAL METRICS
    • 12.9.1 FINANCIAL METRICS
    • 12.9.2 COMPANY VALUATION
  • 12.10 COMPETITIVE SCENARIO
    • 12.10.1 PRODUCT & SERVICE LAUNCHES AND APPROVALS
    • 12.10.2 DEALS
    • 12.10.3 EXPANSIONS
    • 12.10.4 OTHER DEVELOPMENTS

13 COMPANY PROFILES

  • 13.1 KEY PLAYERS
    • 13.1.1 KONINKLIJKE PHILIPS N.V.
      • 13.1.1.1 Business overview
      • 13.1.1.2 Products & services offered
      • 13.1.1.3 Recent developments
        • 13.1.1.3.1 Product launches
        • 13.1.1.3.2 Deals
        • 13.1.1.3.3 Expansions
      • 13.1.1.4 MnM view
        • 13.1.1.4.1 Key strengths
        • 13.1.1.4.2 Strategic choices
        • 13.1.1.4.3 Weaknesses & competitive threats
    • 13.1.2 BECTON, DICKINSON AND COMPANY
      • 13.1.2.1 Business overview
      • 13.1.2.2 Products & services offered
      • 13.1.2.3 Recent developments
        • 13.1.2.3.1 Product launches & approvals
        • 13.1.2.3.2 Deals
      • 13.1.2.4 MnM view
        • 13.1.2.4.1 Key strengths
        • 13.1.2.4.2 Strategic choices
        • 13.1.2.4.3 Weaknesses & competitive threats
    • 13.1.3 ABBOTT LABORATORIES
      • 13.1.3.1 Business overview
      • 13.1.3.2 Products & services offered
      • 13.1.3.3 Recent developments
        • 13.1.3.3.1 Product approvals
      • 13.1.3.4 MnM view
        • 13.1.3.4.1 Key strengths
        • 13.1.3.4.2 Strategic choices
        • 13.1.3.4.3 Weaknesses & competitive threats
    • 13.1.4 THERMO FISHER SCIENTIFIC INC.
      • 13.1.4.1 Business overview
      • 13.1.4.2 Products & services offered
      • 13.1.4.3 Recent developments
        • 13.1.4.3.1 Product & service launches
        • 13.1.4.3.2 Deals
      • 13.1.4.4 MnM view
        • 13.1.4.4.1 Key strengths
        • 13.1.4.4.2 Strategic choices
        • 13.1.4.4.3 Weaknesses & competitive threats
    • 13.1.5 GE HEALTHCARE TECHNOLOGIES, INC.
      • 13.1.5.1 Business overview
      • 13.1.5.2 Products & services offered
      • 13.1.5.3 Recent developments
        • 13.1.5.3.1 Product & service launches & approvals
        • 13.1.5.3.2 Deals
        • 13.1.5.3.3 Other developments
      • 13.1.5.4 MnM view
        • 13.1.5.4.1 Key strengths
        • 13.1.5.4.2 Strategic choices
        • 13.1.5.4.3 Weaknesses & competitive threats
    • 13.1.6 BIO-RAD LABORATORIES, INC.
      • 13.1.6.1 Business overview
      • 13.1.6.2 Products & services offered
      • 13.1.6.3 Recent developments
        • 13.1.6.3.1 Product launches & approvals
        • 13.1.6.3.2 Deals
    • 13.1.7 BIOMERIEUX
      • 13.1.7.1 Business overview
      • 13.1.7.2 Products & services offered
      • 13.1.7.3 Recent developments
        • 13.1.7.3.1 Product launches & approvals
        • 13.1.7.3.2 Deals
    • 13.1.8 REVVITY, INC.
      • 13.1.8.1 Business overview
      • 13.1.8.2 Products & services offered
      • 13.1.8.3 Recent developments
        • 13.1.8.3.1 Product launches & approvals
        • 13.1.8.3.2 Deals
    • 13.1.9 SEEGENE INC.
      • 13.1.9.1 Business overview
      • 13.1.9.2 Products & services offered
      • 13.1.9.3 Recent developments
        • 13.1.9.3.1 Product launches & approvals
        • 13.1.9.3.2 Deals
        • 13.1.9.3.3 Expansions
        • 13.1.9.3.4 Other developments
    • 13.1.10 NIHON KOHDEN CORPORATION
      • 13.1.10.1 Business overview
      • 13.1.10.2 Products & services offered
    • 13.1.11 VITALOGRAPH
      • 13.1.11.1 Business overview
      • 13.1.11.2 Products & services offered
      • 13.1.11.3 Recent developments
        • 13.1.11.3.1 Product & service launches & approvals
        • 13.1.11.3.2 Deals
    • 13.1.12 SDI DIAGNOSTICS
      • 13.1.12.1 Business overview
      • 13.1.12.2 Products & services offered
    • 13.1.13 RESMED INC.
      • 13.1.13.1 Business overview
      • 13.1.13.2 Products & services offered
      • 13.1.13.3 Recent developments
        • 13.1.13.3.1 Deals
        • 13.1.13.3.2 Expansions
        • 13.1.13.3.3 Other developments
    • 13.1.14 SIEMENS HEALTHINEERS AG
      • 13.1.14.1 Business overview
      • 13.1.14.2 Products & services offered
      • 13.1.14.3 Recent developments
        • 13.1.14.3.1 Product launches
        • 13.1.14.3.2 Deals
        • 13.1.14.3.3 Expansions
    • 13.1.15 COSMED SRL
      • 13.1.15.1 Business overview
      • 13.1.15.2 Products & services offered
      • 13.1.15.3 Recent developments
        • 13.1.15.3.1 Product launches
        • 13.1.15.3.2 Deals
    • 13.1.16 HOLOGIC, INC.
      • 13.1.16.1 Business overview
      • 13.1.16.2 Products & services offered
      • 13.1.16.3 Recent developments
        • 13.1.16.3.1 Product launches
        • 13.1.16.3.2 Deals
    • 13.1.17 QIAGEN N.V.
      • 13.1.17.1 Business overview
      • 13.1.17.2 Products & services offered
      • 13.1.17.3 Recent developments
        • 13.1.17.3.1 Product launches
        • 13.1.17.3.2 Deals
        • 13.1.17.3.3 Other developments
  • 13.2 OTHER PLAYERS
    • 13.2.1 MGC DIAGNOSTICS CORPORATION
    • 13.2.2 VISBY MEDICAL, INC.
    • 13.2.3 BRIOTA TECHNOLOGIES PVT. LTD.
    • 13.2.4 BIRD HEALTHCARE
    • 13.2.5 LOWENSTEIN MEDICAL SE & CO. KG
    • 13.2.6 PROAXSIS
    • 13.2.7 NDD MEDICAL TECHNOLOGIES
    • 13.2.8 COMPUMEDICS LIMITED

14 APPENDIX

  • 14.1 DISCUSSION GUIDE
  • 14.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
  • 14.3 CUSTOMIZATION OPTIONS
  • 14.4 RELATED REPORTS
  • 14.5 AUTHOR DETAILS

List of Tables

  • TABLE 1 RESPIRATORY DIAGNOSTICS MARKET: INCLUSIONS & EXCLUSIONS
  • TABLE 2 EXCHANGE RATES UTILIZED FOR CONVERSION TO USD
  • TABLE 3 RESPIRATORY DIAGNOSTICS MARKET: STUDY ASSUMPTIONS
  • TABLE 4 RESPIRATORY DIAGNOSTICS MARKET: RISK ASSESSMENT ANALYSIS
  • TABLE 5 AWARENESS INITIATIVES ON EFFECTS OF UNTREATED SLEEP APNEA
  • TABLE 6 RESPIRATORY DIAGNOSTICS MARKET: PORTER'S FIVE FORCES ANALYSIS
  • TABLE 7 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 8 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 9 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 10 LATIN AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 11 MIDDLE EAST & AFRICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 12 US: CLASSIFICATION OF MEDICAL EQUIPMENT
  • TABLE 13 US: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS
  • TABLE 14 CANADA: LEVEL OF RISK, TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS
  • TABLE 15 EUROPE: LEVEL OF RISK, TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS
  • TABLE 16 CHINA: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS
  • TABLE 17 JAPAN: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS
  • TABLE 18 RESPIRATORY DIAGNOSTICS MARKET: INNOVATIONS AND PATENT REGISTRATIONS, 2022-2024
  • TABLE 19 IMPORT DATA FOR HS CODE 901819, BY COUNTRY, 2019-2023 (USD THOUSAND)
  • TABLE 20 EXPORT DATA FOR HS CODE 901819, BY COUNTRY, 2019-2023 (USD THOUSAND)
  • TABLE 21 AVERAGE SELLING PRICE TREND OF RESPIRATORY DIAGNOSTIC PRODUCTS, BY REGION, 2021-2023 (USD)
  • TABLE 22 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR RESPIRATORY DIAGNOSTIC DEVICES
  • TABLE 23 KEY BUYING CRITERIA FOR RESPIRATORY DIAGNOSTIC DEVICES
  • TABLE 24 RESPIRATORY DIAGNOSTICS MARKET: KEY CONFERENCES & EVENTS, 2024-2025
  • TABLE 25 RESPIRATORY DIAGNOSTICS MARKET: ROLE IN ECOSYSTEM
  • TABLE 26 CASE STUDY 1: ACUPEBBLE SA100 - TRANSFORMING SLEEP APNEA DIAGNOSIS
  • TABLE 27 CASE STUDY 2: REMOTE MONITORING SOLUTION FOR COVID-19 PATIENTS IN INDONESIA
  • TABLE 28 CASE STUDY 3: EFFECTIVE MANAGEMENT OF A 71-YEAR-OLD COPD PATIENT WITH ACUTE EXACERBATIONS
  • TABLE 29 RESPIRATORY DIAGNOSTICS MARKET: REIMBURSEMENT SCENARIO
  • TABLE 30 RESPIRATORY DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2022-2030 (USD MILLION)
  • TABLE 31 RESPIRATORY DIAGNOSTICS MARKET FOR INSTRUMENTS & DEVICES, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 32 RESPIRATORY DIAGNOSTICS MARKET FOR ASSAYS & REAGENTS, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 33 RESPIRATORY DIAGNOSTICS MARKET FOR SERVICES & SOFTWARE, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 34 RESPIRATORY DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2030 (USD MILLION)
  • TABLE 35 RESPIRATORY DIAGNOSTICS MARKET FOR MECHANICAL TESTS, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 36 RESPIRATORY DIAGNOSTICS MARKET FOR MECHANICAL TESTS, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 37 RESPIRATORY DIAGNOSTICS MARKET FOR PULMONARY FUNCTION TESTS, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 38 RESPIRATORY DIAGNOSTICS MARKET FOR PULMONARY FUNCTION TESTS, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 39 SPIROMETRY TESTS MARKET, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 40 SPIROMETRY TESTS MARKET, BY REGION, 2022-2030 (THOUSAND UNITS)
  • TABLE 41 PEAK FLOW TESTS MARKET, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 42 PEAK FLOW TESTS MARKET, BY REGION, 2022-2030 (THOUSAND UNITS)
  • TABLE 43 OTHER PULMONARY TESTS MARKET, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 44 OTHER PULMONARY TESTS MARKET, BY REGION, 2022-2030 (THOUSAND UNITS)
  • TABLE 45 OBSTRUCTIVE SLEEP APNEA DIAGNOSTIC TESTS MARKET, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 46 OTHER MECHANICAL TESTS MARKET, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 47 RESPIRATORY DIAGNOSTICS MARKET FOR IMAGING TESTS, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 48 RESPIRATORY DIAGNOSTICS MARKET FOR IMAGING TESTS, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 49 X-RAY MARKET, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 50 COMPUTED TOMOGRAPHY MARKET, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 51 MAGNETIC RESONANCE IMAGING MARKET, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 52 POSITRON EMISSION TOMOGRAPHY MARKET, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 53 OTHER IMAGING TESTS MARKET, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 54 RESPIRATORY DIAGNOSTICS MARKET FOR TRADITIONAL DIAGNOSTIC TESTS, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 55 RESPIRATORY DIAGNOSTICS MARKET FOR TRADITIONAL DIAGNOSTIC TESTS, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 56 IMMUNODIAGNOSTICS MARKET, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 57 BIOCHEMICAL TESTS MARKET, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 58 MICROSCOPY MARKET, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 59 RESPIRATORY DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTIC TESTS, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 60 RESPIRATORY DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTIC TESTS, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 61 PCR MARKET, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 62 NUCLEIC ACID AMPLIFICATION TEST MARKET, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 63 IN SITU HYBRIDIZATION MARKET, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 64 DNA SEQUENCING & NEXT-GENERATION SEQUENCING MARKET, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 65 MICROARRAYS MARKET, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 66 OTHER MOLECULAR DIAGNOSTIC TESTS MARKET, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 67 RESPIRATORY DIAGNOSTICS MARKET, BY DISEASE TYPE, 2022-2030 (USD MILLION)
  • TABLE 68 RESPIRATORY DIAGNOSTICS MARKET FOR TUBERCULOSIS, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 69 RESPIRATORY DIAGNOSTICS MARKET FOR ASTHMA, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 70 RESPIRATORY DIAGNOSTICS MARKET FOR LUNG CANCER, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 71 RESPIRATORY DIAGNOSTICS MARKET FOR LUNG CANCER, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 72 NON-SMALL-CELL LUNG CANCER MARKET, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 73 SMALL-CELL LUNG CANCER MARKET, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 74 OTHER LUNG CANCERS MARKET, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 75 RESPIRATORY DIAGNOSTICS MARKET FOR CHRONIC OBSTRUCTIVE PULMONARY DISEASE, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 76 RESPIRATORY DIAGNOSTICS MARKET FOR PNEUMONIA, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 77 RESPIRATORY DIAGNOSTICS MARKET FOR OTHER DISEASES, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 78 RESPIRATORY DIAGNOSTICS MARKET, BY DIAGNOSIS TYPE, 2022-2030 (USD MILLION)
  • TABLE 79 SYNDROMIC DIAGNOSIS MARKET, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 80 ETIOLOGICAL DIAGNOSIS MARKET, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 81 PROGNOSIS DIAGNOSIS MARKET, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 82 RESPIRATORY DIAGNOSTICS MARKET, BY END USER, 2022-2030 (USD MILLION)
  • TABLE 83 RESPIRATORY DIAGNOSTICS MARKET FOR HOSPITALS & CLINICS, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 84 RESPIRATORY DIAGNOSTICS MARKET FOR DIAGNOSTIC LABORATORIES, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 85 RESPIRATORY DIAGNOSTICS MARKET FOR LONG-TERM CARE & SPECIALTY CENTERS, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 86 RESPIRATORY DIAGNOSTICS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 87 RESPIRATORY DIAGNOSTICS MARKET, BY REGION, 2022-2030 (USD MILLION)
  • TABLE 88 NORTH AMERICA: RESPIRATORY DIAGNOSTICS MARKET, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 89 NORTH AMERICA: RESPIRATORY DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2022-2030 (USD MILLION)
  • TABLE 90 NORTH AMERICA: RESPIRATORY DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2030 (USD MILLION)
  • TABLE 91 NORTH AMERICA: MECHANICAL TESTS MARKET, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 92 NORTH AMERICA: PULMONARY FUNCTION TESTS MARKET, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 93 NORTH AMERICA: IMAGING TESTS MARKET, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 94 NORTH AMERICA: TRADITIONAL DIAGNOSTIC TESTS MARKET, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 95 NORTH AMERICA: MOLECULAR DIAGNOSTIC TESTS MARKET, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 96 NORTH AMERICA: RESPIRATORY DIAGNOSTICS MARKET, BY DISEASE TYPE, 2022-2030 (USD MILLION)
  • TABLE 97 NORTH AMERICA: LUNG CANCER MARKET, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 98 NORTH AMERICA: RESPIRATORY DIAGNOSTICS MARKET, BY DIAGNOSIS TYPE, 2022-2030 (USD MILLION)
  • TABLE 99 NORTH AMERICA: RESPIRATORY DIAGNOSTICS MARKET, BY END USER, 2022-2030 (USD MILLION)
  • TABLE 100 US: KEY MACROINDICATORS
  • TABLE 101 US: RESPIRATORY DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2022-2030 (USD MILLION)
  • TABLE 102 US: RESPIRATORY DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2030 (USD MILLION)
  • TABLE 103 US: MECHANICAL TESTS MARKET, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 104 US: PULMONARY FUNCTION TESTS MARKET, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 105 US: IMAGING TESTS MARKET, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 106 US: TRADITIONAL DIAGNOSTIC TESTS MARKET, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 107 US: MOLECULAR DIAGNOSTIC TESTS MARKET, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 108 US: RESPIRATORY DIAGNOSTICS MARKET, BY DISEASE TYPE, 2022-2030 (USD MILLION)
  • TABLE 109 US: LUNG CANCER MARKET, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 110 US: RESPIRATORY DIAGNOSTICS MARKET, BY DIAGNOSIS TYPE, 2022-2030 (USD MILLION)
  • TABLE 111 US: RESPIRATORY DIAGNOSTICS MARKET, BY END USER, 2022-2030 (USD MILLION)
  • TABLE 112 CANADA: KEY MACROINDICATORS
  • TABLE 113 CANADA: RESPIRATORY DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2022-2030 (USD MILLION)
  • TABLE 114 CANADA: RESPIRATORY DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2030 (USD MILLION)
  • TABLE 115 CANADA: MECHANICAL TESTS MARKET, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 116 CANADA: PULMONARY FUNCTION TESTS MARKET, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 117 CANADA: IMAGING TESTS MARKET, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 118 CANADA: TRADITIONAL DIAGNOSTIC TESTS MARKET, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 119 CANADA: MOLECULAR DIAGNOSTIC TESTS MARKET, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 120 CANADA: RESPIRATORY DIAGNOSTICS MARKET, BY DISEASE TYPE, 2022-2030 (USD MILLION)
  • TABLE 121 CANADA: LUNG CANCER MARKET, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 122 CANADA: RESPIRATORY DIAGNOSTICS MARKET, BY DIAGNOSIS TYPE, 2022-2030 (USD MILLION)
  • TABLE 123 CANADA: RESPIRATORY DIAGNOSTICS MARKET, BY END USER, 2022-2030 (USD MILLION)
  • TABLE 124 EUROPE: RESPIRATORY DIAGNOSTICS MARKET, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 125 EUROPE: RESPIRATORY DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2022-2030 (USD MILLION)
  • TABLE 126 EUROPE: RESPIRATORY DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2030 (USD MILLION)
  • TABLE 127 EUROPE: MECHANICAL TESTS MARKET, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 128 EUROPE: PULMONARY FUNCTION TESTS MARKET, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 129 EUROPE: IMAGING TESTS MARKET, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 130 EUROPE: TRADITIONAL DIAGNOSTIC TESTS MARKET, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 131 EUROPE: MOLECULAR DIAGNOSTIC TESTS MARKET, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 132 EUROPE: RESPIRATORY DIAGNOSTICS MARKET, BY DISEASE TYPE, 2022-2030 (USD MILLION)
  • TABLE 133 EUROPE: LUNG CANCER MARKET, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 134 EUROPE: RESPIRATORY DIAGNOSTICS MARKET, BY DIAGNOSIS TYPE, 2022-2030 (USD MILLION)
  • TABLE 135 EUROPE: RESPIRATORY DIAGNOSTICS MARKET, BY END USER, 2022-2030 (USD MILLION)
  • TABLE 136 GERMANY: KEY MACROINDICATORS
  • TABLE 137 GERMANY: RESPIRATORY DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2022-2030 (USD MILLION)
  • TABLE 138 GERMANY: RESPIRATORY DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2030 (USD MILLION)
  • TABLE 139 GERMANY: MECHANICAL TESTS MARKET, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 140 GERMANY: PULMONARY FUNCTION TESTS MARKET, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 141 GERMANY: IMAGING TESTS MARKET, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 142 GERMANY: TRADITIONAL DIAGNOSTIC TESTS MARKET, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 143 GERMANY: MOLECULAR DIAGNOSTIC TESTS MARKET, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 144 GERMANY: RESPIRATORY DIAGNOSTICS MARKET, BY DISEASE TYPE, 2022-2030 (USD MILLION)
  • TABLE 145 GERMANY: LUNG CANCER MARKET, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 146 GERMANY: RESPIRATORY DIAGNOSTICS MARKET, BY DIAGNOSIS TYPE, 2022-2030 (USD MILLION)
  • TABLE 147 GERMANY: RESPIRATORY DIAGNOSTICS MARKET, BY END USER, 2022-2030 (USD MILLION)
  • TABLE 148 UK: KEY MACROINDICATORS
  • TABLE 149 UK: RESPIRATORY DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2022-2030 (USD MILLION)
  • TABLE 150 UK: RESPIRATORY DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2030 (USD MILLION)
  • TABLE 151 UK: MECHANICAL TESTS MARKET, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 152 UK: PULMONARY FUNCTION TESTS MARKET, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 153 UK: IMAGING TESTS MARKET, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 154 UK: TRADITIONAL DIAGNOSTIC TESTS MARKET, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 155 UK: MOLECULAR DIAGNOSTIC TESTS MARKET, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 156 UK: RESPIRATORY DIAGNOSTICS MARKET, BY DISEASE TYPE, 2022-2030 (USD MILLION)
  • TABLE 157 UK: LUNG CANCER MARKET, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 158 UK: RESPIRATORY DIAGNOSTICS MARKET, BY DIAGNOSIS TYPE, 2022-2030 (USD MILLION)
  • TABLE 159 UK: RESPIRATORY DIAGNOSTICS MARKET, BY END USER, 2022-2030 (USD MILLION)
  • TABLE 160 FRANCE: KEY MACROINDICATORS
  • TABLE 161 FRANCE: RESPIRATORY DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2022-2030 (USD MILLION)
  • TABLE 162 FRANCE: RESPIRATORY DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2030 (USD MILLION)
  • TABLE 163 FRANCE: MECHANICAL TESTS MARKET, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 164 FRANCE: PULMONARY FUNCTION TESTS MARKET, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 165 FRANCE: IMAGING TESTS MARKET, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 166 FRANCE: TRADITIONAL DIAGNOSTIC TESTS MARKET, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 167 FRANCE: MOLECULAR DIAGNOSTIC TESTS MARKET, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 168 FRANCE: RESPIRATORY DIAGNOSTICS MARKET, BY DISEASE TYPE, 2022-2030 (USD MILLION)
  • TABLE 169 FRANCE: LUNG CANCER MARKET, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 170 FRANCE: RESPIRATORY DIAGNOSTICS MARKET, BY DIAGNOSIS TYPE, 2022-2030 (USD MILLION)
  • TABLE 171 FRANCE: RESPIRATORY DIAGNOSTICS MARKET, BY END USER, 2022-2030 (USD MILLION)
  • TABLE 172 ITALY: KEY MACROINDICATORS
  • TABLE 173 ITALY: RESPIRATORY DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2022-2030 (USD MILLION)
  • TABLE 174 ITALY: RESPIRATORY DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2030 (USD MILLION)
  • TABLE 175 ITALY: MECHANICAL TESTS MARKET, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 176 ITALY: PULMONARY FUNCTION TESTS MARKET, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 177 ITALY: IMAGING TESTS MARKET, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 178 ITALY: TRADITIONAL DIAGNOSTIC TESTS MARKET, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 179 ITALY: MOLECULAR DIAGNOSTIC TESTS MARKET, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 180 ITALY: RESPIRATORY DIAGNOSTICS MARKET, BY DISEASE TYPE, 2022-2030 (USD MILLION)
  • TABLE 181 ITALY: LUNG CANCER MARKET, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 182 ITALY: RESPIRATORY DIAGNOSTICS MARKET, BY DIAGNOSIS TYPE, 2022-2030 (USD MILLION)
  • TABLE 183 ITALY: RESPIRATORY DIAGNOSTICS MARKET, BY END USER, 2022-2030 (USD MILLION)
  • TABLE 184 SPAIN: KEY MACROINDICATORS
  • TABLE 185 SPAIN: RESPIRATORY DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2022-2030 (USD MILLION)
  • TABLE 186 SPAIN: RESPIRATORY DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2030 (USD MILLION)
  • TABLE 187 SPAIN: MECHANICAL TESTS MARKET, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 188 SPAIN: PULMONARY FUNCTION TESTS MARKET, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 189 SPAIN: IMAGING TESTS MARKET, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 190 SPAIN: TRADITIONAL DIAGNOSTIC TESTS MARKET, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 191 SPAIN: MOLECULAR DIAGNOSTIC TESTS MARKET, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 192 SPAIN: RESPIRATORY DIAGNOSTICS MARKET, BY DISEASE TYPE, 2022-2030 (USD MILLION)
  • TABLE 193 SPAIN: LUNG CANCER MARKET, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 194 SPAIN: RESPIRATORY DIAGNOSTICS MARKET, BY DIAGNOSIS TYPE, 2022-2030 (USD MILLION)
  • TABLE 195 SPAIN: RESPIRATORY DIAGNOSTICS MARKET, BY END USER, 2022-2030 (USD MILLION)
  • TABLE 196 REST OF EUROPE: RESPIRATORY DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2022-2030 (USD MILLION)
  • TABLE 197 REST OF EUROPE: RESPIRATORY DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2030 (USD MILLION)
  • TABLE 198 REST OF EUROPE: MECHANICAL TESTS MARKET, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 199 REST OF EUROPE: PULMONARY FUNCTION TESTS MARKET, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 200 REST OF EUROPE: IMAGING TESTS MARKET, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 201 REST OF EUROPE: TRADITIONAL DIAGNOSTIC TESTS MARKET, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 202 REST OF EUROPE: MOLECULAR DIAGNOSTIC TESTS MARKET, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 203 REST OF EUROPE: RESPIRATORY DIAGNOSTICS MARKET, BY DISEASE TYPE, 2022-2030 (USD MILLION)
  • TABLE 204 REST OF EUROPE: LUNG CANCER MARKET, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 205 REST OF EUROPE: RESPIRATORY DIAGNOSTICS MARKET, BY DIAGNOSIS TYPE, 2022-2030 (USD MILLION)
  • TABLE 206 REST OF EUROPE: RESPIRATORY DIAGNOSTICS MARKET, BY END USER, 2022-2030 (USD MILLION)
  • TABLE 207 ASIA PACIFIC: RESPIRATORY DIAGNOSTICS MARKET, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 208 ASIA PACIFIC: RESPIRATORY DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2022-2030 (USD MILLION)
  • TABLE 209 ASIA PACIFIC: RESPIRATORY DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2030 (USD MILLION)
  • TABLE 210 ASIA PACIFIC: MECHANICAL TESTS MARKET, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 211 ASIA PACIFIC: PULMONARY FUNCTION TESTS MARKET, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 212 ASIA PACIFIC: IMAGING TESTS MARKET, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 213 ASIA PACIFIC: TRADITIONAL DIAGNOSTIC TESTS MARKET, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 214 ASIA PACIFIC: MOLECULAR DIAGNOSTIC TESTS MARKET, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 215 ASIA PACIFIC: RESPIRATORY DIAGNOSTICS MARKET, BY DISEASE TYPE, 2022-2030 (USD MILLION)
  • TABLE 216 ASIA PACIFIC: LUNG CANCER MARKET, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 217 ASIA PACIFIC: RESPIRATORY DIAGNOSTICS MARKET, BY DIAGNOSIS TYPE, 2022-2030 (USD MILLION)
  • TABLE 218 ASIA PACIFIC: RESPIRATORY DIAGNOSTICS MARKET, BY END USER, 2022-2030 (USD MILLION)
  • TABLE 219 JAPAN: KEY MACROINDICATORS
  • TABLE 220 JAPAN: RESPIRATORY DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2022-2030 (USD MILLION)
  • TABLE 221 JAPAN: RESPIRATORY DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2030 (USD MILLION)
  • TABLE 222 JAPAN: MECHANICAL TESTS MARKET, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 223 JAPAN: PULMONARY FUNCTION TESTS MARKET, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 224 JAPAN: IMAGING TESTS MARKET, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 225 JAPAN: TRADITIONAL DIAGNOSTIC TESTS MARKET, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 226 JAPAN: MOLECULAR DIAGNOSTIC TESTS MARKET, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 227 JAPAN: RESPIRATORY DIAGNOSTICS MARKET, BY DISEASE TYPE, 2022-2030 (USD MILLION)
  • TABLE 228 JAPAN: LUNG CANCER MARKET, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 229 JAPAN: RESPIRATORY DIAGNOSTICS MARKET, BY DIAGNOSIS TYPE, 2022-2030 (USD MILLION)
  • TABLE 230 JAPAN: RESPIRATORY DIAGNOSTICS MARKET, BY END USER, 2022-2030 (USD MILLION)
  • TABLE 231 CHINA: KEY MACROINDICATORS
  • TABLE 232 CHINA: RESPIRATORY DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2022-2030 (USD MILLION)
  • TABLE 233 CHINA: RESPIRATORY DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2030 (USD MILLION)
  • TABLE 234 CHINA: MECHANICAL TESTS MARKET, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 235 CHINA: PULMONARY FUNCTION TESTS MARKET, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 236 CHINA: IMAGING TESTS MARKET, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 237 CHINA: TRADITIONAL DIAGNOSTIC TESTS MARKET, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 238 CHINA: MOLECULAR DIAGNOSTIC TESTS MARKET, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 239 CHINA: RESPIRATORY DIAGNOSTICS MARKET, BY DISEASE TYPE, 2022-2030 (USD MILLION)
  • TABLE 240 CHINA: LUNG CANCER MARKET, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 241 CHINA: RESPIRATORY DIAGNOSTICS MARKET, BY DIAGNOSIS TYPE, 2022-2030 (USD MILLION)
  • TABLE 242 CHINA: RESPIRATORY DIAGNOSTICS MARKET, BY END USER, 2022-2030 (USD MILLION)
  • TABLE 243 INDIA: KEY MACROINDICATORS
  • TABLE 244 INDIA: RESPIRATORY DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2022-2030 (USD MILLION)
  • TABLE 245 INDIA: RESPIRATORY DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2030 (USD MILLION)
  • TABLE 246 INDIA: MECHANICAL TESTS MARKET, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 247 INDIA: PULMONARY FUNCTION TESTS MARKET, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 248 INDIA: IMAGING TESTS MARKET, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 249 INDIA: TRADITIONAL DIAGNOSTIC TESTS MARKET, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 250 INDIA: MOLECULAR DIAGNOSTIC TESTS MARKET, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 251 INDIA: RESPIRATORY DIAGNOSTICS MARKET, BY DISEASE TYPE, 2022-2030 (USD MILLION)
  • TABLE 252 INDIA: LUNG CANCER MARKET, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 253 INDIA: RESPIRATORY DIAGNOSTICS MARKET, BY DIAGNOSIS TYPE, 2022-2030 (USD MILLION)
  • TABLE 254 INDIA: RESPIRATORY DIAGNOSTICS MARKET, BY END USER, 2022-2030 (USD MILLION)
  • TABLE 255 AUSTRALIA: KEY MACROINDICATORS
  • TABLE 256 AUSTRALIA: RESPIRATORY DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2022-2030 (USD MILLION)
  • TABLE 257 AUSTRALIA: RESPIRATORY DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2030 (USD MILLION)
  • TABLE 258 AUSTRALIA: MECHANICAL TESTS MARKET, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 259 AUSTRALIA: PULMONARY FUNCTION TESTS MARKET, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 260 AUSTRALIA: IMAGING TESTS MARKET, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 261 AUSTRALIA: TRADITIONAL DIAGNOSTIC TESTS MARKET, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 262 AUSTRALIA: MOLECULAR DIAGNOSTIC TESTS MARKET, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 263 AUSTRALIA: RESPIRATORY DIAGNOSTICS MARKET, BY DISEASE TYPE, 2022-2030 (USD MILLION)
  • TABLE 264 AUSTRALIA: LUNG CANCER MARKET, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 265 AUSTRALIA: RESPIRATORY DIAGNOSTICS MARKET, BY DIAGNOSIS TYPE, 2022-2030 (USD MILLION)
  • TABLE 266 AUSTRALIA: RESPIRATORY DIAGNOSTICS MARKET, BY END USER, 2022-2030 (USD MILLION)
  • TABLE 267 SOUTH KOREA: KEY MACROINDICATORS
  • TABLE 268 SOUTH KOREA: RESPIRATORY DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2022-2030 (USD MILLION)
  • TABLE 269 SOUTH KOREA: RESPIRATORY DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2030 (USD MILLION)
  • TABLE 270 SOUTH KOREA: MECHANICAL TESTS MARKET, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 271 SOUTH KOREA: PULMONARY FUNCTION TESTS MARKET, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 272 SOUTH KOREA: IMAGING TESTS MARKET, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 273 SOUTH KOREA: TRADITIONAL DIAGNOSTIC TESTS MARKET, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 274 SOUTH KOREA: MOLECULAR DIAGNOSTIC TESTS MARKET, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 275 SOUTH KOREA: RESPIRATORY DIAGNOSTICS MARKET, BY DISEASE TYPE, 2022-2030 (USD MILLION)
  • TABLE 276 SOUTH KOREA: LUNG CANCER MARKET, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 277 SOUTH KOREA: RESPIRATORY DIAGNOSTICS MARKET, BY DIAGNOSIS TYPE, 2022-2030 (USD MILLION)
  • TABLE 278 SOUTH KOREA: RESPIRATORY DIAGNOSTICS MARKET, BY END USER, 2022-2030 (USD MILLION)
  • TABLE 279 REST OF ASIA PACIFIC: RESPIRATORY DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2022-2030 (USD MILLION)
  • TABLE 280 REST OF ASIA PACIFIC: RESPIRATORY DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2030 (USD MILLION)
  • TABLE 281 REST OF ASIA PACIFIC: MECHANICAL TESTS MARKET, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 282 REST OF ASIA PACIFIC: PULMONARY FUNCTION TESTS MARKET, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 283 REST OF ASIA PACIFIC: IMAGING TESTS MARKET, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 284 REST OF ASIA PACIFIC: TRADITIONAL DIAGNOSTIC TESTS MARKET, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 285 REST OF ASIA PACIFIC: MOLECULAR DIAGNOSTIC TESTS MARKET, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 286 REST OF ASIA PACIFIC: RESPIRATORY DIAGNOSTICS MARKET, BY DISEASE TYPE, 2022-2030 (USD MILLION)
  • TABLE 287 REST OF ASIA PACIFIC: LUNG CANCER MARKET, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 288 REST OF ASIA PACIFIC: RESPIRATORY DIAGNOSTICS MARKET, BY DIAGNOSIS TYPE, 2022-2030 (USD MILLION)
  • TABLE 289 REST OF ASIA PACIFIC: RESPIRATORY DIAGNOSTICS MARKET, BY END USER, 2022-2030 (USD MILLION)
  • TABLE 290 LATIN AMERICA: RESPIRATORY DIAGNOSTICS MARKET, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 291 LATIN AMERICA: RESPIRATORY DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2022-2030 (USD MILLION)
  • TABLE 292 LATIN AMERICA: RESPIRATORY DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2030 (USD MILLION)
  • TABLE 293 LATIN AMERICA: MECHANICAL TESTS MARKET, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 294 LATIN AMERICA: PULMONARY FUNCTION TESTS MARKET, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 295 LATIN AMERICA: IMAGING TESTS MARKET, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 296 LATIN AMERICA: TRADITIONAL DIAGNOSTIC TESTS MARKET, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 297 LATIN AMERICA: MOLECULAR DIAGNOSTIC TESTS MARKET, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 298 LATIN AMERICA: RESPIRATORY DIAGNOSTICS MARKET, BY DISEASE TYPE, 2022-2030 (USD MILLION)
  • TABLE 299 LATIN AMERICA: LUNG CANCER MARKET, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 300 LATIN AMERICA: RESPIRATORY DIAGNOSTICS MARKET, BY DIAGNOSIS TYPE, 2022-2030 (USD MILLION)
  • TABLE 301 LATIN AMERICA: RESPIRATORY DIAGNOSTICS MARKET, BY END USER, 2022-2030 (USD MILLION)
  • TABLE 302 BRAZIL: KEY MACROINDICATORS
  • TABLE 303 BRAZIL: RESPIRATORY DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2022-2030 (USD MILLION)
  • TABLE 304 BRAZIL: RESPIRATORY DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2030 (USD MILLION)
  • TABLE 305 BRAZIL: MECHANICAL TESTS MARKET, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 306 BRAZIL: PULMONARY FUNCTION TESTS MARKET, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 307 BRAZIL: IMAGING TESTS MARKET, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 308 BRAZIL: TRADITIONAL DIAGNOSTIC TESTS MARKET, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 309 BRAZIL: MOLECULAR DIAGNOSTIC TESTS MARKET, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 310 BRAZIL: RESPIRATORY DIAGNOSTICS MARKET, BY DISEASE TYPE, 2022-2030 (USD MILLION)
  • TABLE 311 BRAZIL: LUNG CANCER MARKET, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 312 BRAZIL: RESPIRATORY DIAGNOSTICS MARKET, BY DIAGNOSIS TYPE, 2022-2030 (USD MILLION)
  • TABLE 313 BRAZIL: RESPIRATORY DIAGNOSTICS MARKET, BY END USER, 2022-2030 (USD MILLION)
  • TABLE 314 MEXICO: KEY MACROINDICATORS
  • TABLE 315 MEXICO: RESPIRATORY DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2022-2030 (USD MILLION)
  • TABLE 316 MEXICO: RESPIRATORY DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2030 (USD MILLION)
  • TABLE 317 MEXICO: MECHANICAL TESTS MARKET, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 318 MEXICO: PULMONARY FUNCTION TESTS MARKET, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 319 MEXICO: IMAGING TESTS MARKET, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 320 MEXICO: TRADITIONAL DIAGNOSTIC TESTS MARKET, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 321 MEXICO: MOLECULAR DIAGNOSTIC TESTS MARKET, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 322 MEXICO: RESPIRATORY DIAGNOSTICS MARKET, BY DISEASE TYPE, 2022-2030 (USD MILLION)
  • TABLE 323 MEXICO: LUNG CANCER MARKET, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 324 MEXICO: RESPIRATORY DIAGNOSTICS MARKET, BY DIAGNOSIS TYPE, 2022-2030 (USD MILLION)
  • TABLE 325 MEXICO: RESPIRATORY DIAGNOSTICS MARKET, BY END USER, 2022-2030 (USD MILLION)
  • TABLE 326 REST OF LATIN AMERICA: RESPIRATORY DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2022-2030 (USD MILLION)
  • TABLE 327 REST OF LATIN AMERICA: RESPIRATORY DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2030 (USD MILLION)
  • TABLE 328 REST OF LATIN AMERICA: MECHANICAL TESTS MARKET, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 329 REST OF LATIN AMERICA: PULMONARY FUNCTION TESTS MARKET, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 330 REST OF LATIN AMERICA: IMAGING TESTS MARKET, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 331 REST OF LATIN AMERICA: TRADITIONAL DIAGNOSTIC TESTS MARKET, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 332 REST OF LATIN AMERICA: MOLECULAR DIAGNOSTIC TESTS MARKET, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 333 REST OF LATIN AMERICA: RESPIRATORY DIAGNOSTICS MARKET, BY DISEASE TYPE, 2022-2030 (USD MILLION)
  • TABLE 334 REST OF LATIN AMERICA: LUNG CANCER MARKET, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 335 REST OF LATIN AMERICA: RESPIRATORY DIAGNOSTICS MARKET, BY DIAGNOSIS TYPE, 2022-2030 (USD MILLION)
  • TABLE 336 REST OF LATIN AMERICA: RESPIRATORY DIAGNOSTICS MARKET, BY END USER, 2022-2030 (USD MILLION)
  • TABLE 337 MIDDLE EAST & AFRICA: RESPIRATORY DIAGNOSTICS MARKET, BY REGION, 2022-2030 (USD MILLION)
  • TABLE 338 MIDDLE EAST & AFRICA: RESPIRATORY DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2022-2030 (USD MILLION)
  • TABLE 339 MIDDLE EAST & AFRICA: RESPIRATORY DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2030 (USD MILLION)
  • TABLE 340 MIDDLE EAST & AFRICA: MECHANICAL TESTS MARKET, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 341 MIDDLE EAST & AFRICA: PULMONARY FUNCTION TESTS MARKET, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 342 MIDDLE EAST & AFRICA: IMAGING TESTS MARKET, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 343 MIDDLE EAST & AFRICA: TRADITIONAL DIAGNOSTIC TESTS MARKET, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 344 MIDDLE EAST & AFRICA: MOLECULAR DIAGNOSTIC TESTS MARKET, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 345 MIDDLE EAST & AFRICA: RESPIRATORY DIAGNOSTICS MARKET, BY DISEASE TYPE, 2022-2030 (USD MILLION)
  • TABLE 346 MIDDLE EAST & AFRICA: LUNG CANCER MARKET, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 347 MIDDLE EAST & AFRICA: RESPIRATORY DIAGNOSTICS MARKET, BY DIAGNOSIS TYPE, 2022-2030 (USD MILLION)
  • TABLE 348 MIDDLE EAST & AFRICA: RESPIRATORY DIAGNOSTICS MARKET, BY END USER, 2022-2030 (USD MILLION)
  • TABLE 349 GCC COUNTRIES: RESPIRATORY DIAGNOSTICS MARKET, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 350 GCC COUNTRIES: RESPIRATORY DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2022-2030 (USD MILLION)
  • TABLE 351 GCC COUNTRIES: RESPIRATORY DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2030 (USD MILLION)
  • TABLE 352 GCC COUNTRIES: MECHANICAL TESTS MARKET, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 353 GCC COUNTRIES: PULMONARY FUNCTION TESTS MARKET, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 354 GCC COUNTRIES: IMAGING TESTS MARKET, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 355 GCC COUNTRIES: TRADITIONAL DIAGNOSTIC TESTS MARKET, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 356 GCC COUNTRIES: MOLECULAR DIAGNOSTIC TESTS MARKET, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 357 GCC COUNTRIES: RESPIRATORY DIAGNOSTICS MARKET, BY DISEASE TYPE, 2022-2030 (USD MILLION)
  • TABLE 358 GCC COUNTRIES: LUNG CANCER MARKET, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 359 GCC COUNTRIES: RESPIRATORY DIAGNOSTICS MARKET, BY DIAGNOSIS TYPE, 2022-2030 (USD MILLION)
  • TABLE 360 GCC COUNTRIES: RESPIRATORY DIAGNOSTICS MARKET, BY END USER, 2022-2030 (USD MILLION)
  • TABLE 361 KINGDOM OF SAUDI ARABIA: KEY MACROINDICATORS
  • TABLE 362 KINGDOM OF SAUDI ARABIA: RESPIRATORY DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2022-2030 (USD MILLION)
  • TABLE 363 KINGDOM OF SAUDI ARABIA: RESPIRATORY DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2030 (USD MILLION)
  • TABLE 364 KINGDOM OF SAUDI ARABIA: MECHANICAL TESTS MARKET, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 365 KINGDOM OF SAUDI ARABIA: PULMONARY FUNCTION TESTS MARKET, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 366 KINGDOM OF SAUDI ARABIA: IMAGING TESTS MARKET, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 367 KINGDOM OF SAUDI ARABIA: TRADITIONAL DIAGNOSTIC TESTS MARKET, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 368 KINGDOM OF SAUDI ARABIA: MOLECULAR DIAGNOSTIC TESTS MARKET, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 369 KINGDOM OF SAUDI ARABIA: RESPIRATORY DIAGNOSTICS MARKET, BY DISEASE TYPE, 2022-2030 (USD MILLION)
  • TABLE 370 KINGDOM OF SAUDI ARABIA: LUNG CANCER MARKET, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 371 KINGDOM OF SAUDI ARABIA: RESPIRATORY DIAGNOSTICS MARKET, BY DIAGNOSIS TYPE, 2022-2030 (USD MILLION)
  • TABLE 372 KINGDOM OF SAUDI ARABIA: RESPIRATORY DIAGNOSTICS MARKET, BY END USER, 2022-2030 (USD MILLION)
  • TABLE 373 UNITED ARAB EMIRATES: KEY MACROINDICATORS
  • TABLE 374 UNITED ARAB EMIRATES: RESPIRATORY DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2022-2030 (USD MILLION)
  • TABLE 375 UNITED ARAB EMIRATES: RESPIRATORY DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2030 (USD MILLION)
  • TABLE 376 UNITED ARAB EMIRATES: MECHANICAL TESTS MARKET, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 377 UNITED ARAB EMIRATES: PULMONARY FUNCTION TESTS MARKET, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 378 UNITED ARAB EMIRATES: IMAGING TESTS MARKET, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 379 UNITED ARAB EMIRATES: TRADITIONAL DIAGNOSTIC TESTS MARKET, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 380 UNITED ARAB EMIRATES: MOLECULAR DIAGNOSTIC TESTS MARKET, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 381 UNITED ARAB EMIRATES: RESPIRATORY DIAGNOSTICS MARKET, BY DISEASE TYPE, 2022-2030 (USD MILLION)
  • TABLE 382 UNITED ARAB EMIRATES: LUNG CANCER MARKET, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 383 UNITED ARAB EMIRATES: RESPIRATORY DIAGNOSTICS MARKET, BY DIAGNOSIS TYPE, 2022-2030 (USD MILLION)
  • TABLE 384 UNITED ARAB EMIRATES: RESPIRATORY DIAGNOSTICS MARKET, BY END USER, 2022-2030 (USD MILLION)
  • TABLE 385 OTHER GCC COUNTRIES: RESPIRATORY DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2022-2030 (USD MILLION)
  • TABLE 386 OTHER GCC COUNTRIES: RESPIRATORY DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2030 (USD MILLION)
  • TABLE 387 OTHER GCC COUNTRIES: MECHANICAL TESTS MARKET, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 388 OTHER GCC COUNTRIES: PULMONARY FUNCTION TESTS MARKET, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 389 OTHER GCC COUNTRIES: IMAGING TESTS MARKET, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 390 OTHER GCC COUNTRIES: TRADITIONAL DIAGNOSTIC TESTS MARKET, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 391 OTHER GCC COUNTRIES: MOLECULAR DIAGNOSTIC TESTS MARKET, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 392 OTHER GCC COUNTRIES: RESPIRATORY DIAGNOSTICS MARKET, BY DISEASE TYPE, 2022-2030 (USD MILLION)
  • TABLE 393 OTHER GCC COUNTRIES: LUNG CANCER MARKET, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 394 OTHER GCC COUNTRIES: RESPIRATORY DIAGNOSTICS MARKET, BY DIAGNOSIS TYPE, 2022-2030 (USD MILLION)
  • TABLE 395 OTHER GCC COUNTRIES: RESPIRATORY DIAGNOSTICS MARKET, BY END USER, 2022-2030 (USD MILLION)
  • TABLE 396 REST OF MIDDLE EAST & AFRICA: RESPIRATORY DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2022-2030 (USD MILLION)
  • TABLE 397 REST OF MIDDLE EAST & AFRICA: RESPIRATORY DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2030 (USD MILLION)
  • TABLE 398 REST OF MIDDLE EAST & AFRICA: MECHANICAL TESTS MARKET, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 399 REST OF MIDDLE EAST & AFRICA: PULMONARY FUNCTION TESTS MARKET, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 400 REST OF MIDDLE EAST & AFRICA: IMAGING TESTS MARKET, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 401 REST OF MIDDLE EAST & AFRICA: TRADITIONAL DIAGNOSTIC TESTS MARKET, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 402 REST OF MIDDLE EAST & AFRICA: MOLECULAR DIAGNOSTIC TESTS MARKET, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 403 REST OF MIDDLE EAST & AFRICA: RESPIRATORY DIAGNOSTICS MARKET, BY DISEASE TYPE, 2022-2030 (USD MILLION)
  • TABLE 404 REST OF MIDDLE EAST & AFRICA: LUNG CANCER MARKET, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 405 REST OF MIDDLE EAST & AFRICA: RESPIRATORY DIAGNOSTICS MARKET, BY DIAGNOSIS TYPE, 2022-2030 (USD MILLION)
  • TABLE 406 REST OF MIDDLE EAST & AFRICA: RESPIRATORY DIAGNOSTICS MARKET, BY END USER, 2022-2030 (USD MILLION)
  • TABLE 407 RESPIRATORY DIAGNOSTIC MARKET: OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS, JANUARY 2021-DECEMBER 2024
  • TABLE 408 RESPIRATORY DIAGNOSTICS MARKET: DEGREE OF COMPETITION, 2023
  • TABLE 409 RESPIRATORY DIAGNOSTICS MARKET: REGIONAL FOOTPRINT
  • TABLE 410 RESPIRATORY DIAGNOSTICS MARKET: PRODUCT & SERVICE FOOTPRINT
  • TABLE 411 RESPIRATORY DIAGNOSTICS MARKET: TEST TYPE FOOTPRINT
  • TABLE 412 RESPIRATORY DIAGNOSTICS MARKET: DISEASE TYPE FOOTPRINT
  • TABLE 413 RESPIRATORY DIAGNOSTICS MARKET: END-USER FOOTPRINT
  • TABLE 414 RESPIRATORY DIAGNOSTICS MARKET: DETAILED LIST OF KEY STARTUP/SME PLAYERS
  • TABLE 415 RESPIRATORY DIAGNOSTICS MARKET: COMPETITIVE BENCHMARKING OF KEY EMERGING PLAYERS/STARTUPS
  • TABLE 416 RESPIRATORY DIAGNOSTICS MARKET: PRODUCT & SERVICE LAUNCHES AND APPROVALS, JANUARY 2021-DECEMBER 2024
  • TABLE 417 RESPIRATORY DIAGNOSTICS MARKET: DEALS, JANUARY 2021-DECEMBER 2024
  • TABLE 418 RESPIRATORY DIAGNOSTICS MARKET: EXPANSIONS, JANUARY 2021-DECEMBER 2024
  • TABLE 419 RESPIRATORY DIAGNOSTICS MARKET: OTHER DEVELOPMENTS, JANUARY 2021-DECEMBER 2024
  • TABLE 420 KONINKLIJKE PHILIPS N.V.: COMPANY OVERVIEW
  • TABLE 421 KONINKLIJKE PHILIPS N.V.: PRODUCTS & SERVICES OFFERED
  • TABLE 422 KONINKLIJKE PHILIPS N.V.: PRODUCT LAUNCHES, JANUARY 2021-DECEMBER 2024
  • TABLE 423 KONINKLIJKE PHILIPS N.V.: DEALS, JANUARY 2021-DECEMBER 2024
  • TABLE 424 KONINKLIJKE PHILIPS N.V.: EXPANSIONS, JANUARY 2021-DECEMBER 2024
  • TABLE 425 BECTON, DICKINSON AND COMPANY: COMPANY OVERVIEW
  • TABLE 426 BECTON, DICKINSON AND COMPANY: PRODUCTS & SERVICES OFFERED
  • TABLE 427 BECTON, DICKINSON AND COMPANY: PRODUCT LAUNCHES & APPROVALS, JANUARY 2021-DECEMBER 2024
  • TABLE 428 BECTON, DICKINSON AND COMPANY: DEALS, JANUARY 2021-DECEMBER 2024
  • TABLE 429 ABBOTT LABORATORIES: COMPANY OVERVIEW
  • TABLE 430 ABBOTT LABORATORIES: PRODUCTS & SERVICES OFFERED
  • TABLE 431 ABBOTT LABORATORIES: PRODUCT APPROVALS, JANUARY 2021-DECEMBER 2024
  • TABLE 432 THERMO FISHER SCIENTIFIC INC.: COMPANY OVERVIEW
  • TABLE 433 THERMO FISHER SCIENTIFIC INC.: PRODUCTS & SERVICES OFFERED
  • TABLE 434 THERMO FISHER SCIENTIFIC INC.: PRODUCT & SERVICE LAUNCHES, JANUARY 2021-DECEMBER 2024
  • TABLE 435 THERMO FISHER SCIENTIFIC INC.: DEALS, JANUARY 2021-DECEMBER 2024
  • TABLE 436 GE HEALTHCARE TECHNOLOGIES, INC.: COMPANY OVERVIEW
  • TABLE 437 GE HEALTHCARE TECHNOLOGIES, INC.: PRODUCTS & SERVICES OFFERED
  • TABLE 438 GE HEALTHCARE TECHNOLOGIES, INC.: PRODUCT & SERVICE LAUNCHES & APPROVALS, JANUARY 2021-DECEMBER 2024
  • TABLE 439 GE HEALTHCARE TECHNOLOGIES, INC.: DEALS, JANUARY 2021-DECEMBER 2024
  • TABLE 440 GE HEALTHCARE TECHNOLOGIES, INC.: OTHER DEVELOPMENTS, JANUARY 2021-MARCH 2024
  • TABLE 441 BIO-RAD LABORATORIES, INC.: COMPANY OVERVIEW
  • TABLE 442 BIO-RAD LABORATORIES, INC.: PRODUCTS & SERVICES OFFERED
  • TABLE 443 BIO-RAD LABORATORIES, INC.: PRODUCT LAUNCHES & APPROVALS, JANUARY 2021-DECEMBER 2024
  • TABLE 444 BIO-RAD LABORATORIES, INC.: DEALS, JANUARY 2021-DECEMBER 2024
  • TABLE 445 BIOMERIEUX: COMPANY OVERVIEW
  • TABLE 446 BIOMERIEUX: PRODUCTS & SERVICES OFFERED
  • TABLE 447 BIOMERIEUX: PRODUCT LAUNCHES & APPROVALS, JANUARY 2021-DECEMBER 2024
  • TABLE 448 BIOMERIEUX: DEALS, JANUARY 2021-DECEMBER 2024
  • TABLE 449 REVVITY, INC.: COMPANY OVERVIEW
  • TABLE 450 REVVITY, INC.: PRODUCTS & SERVICES OFFERED
  • TABLE 451 REVVITY, INC.: PRODUCT LAUNCHES & APPROVALS, JANUARY 2021-DECEMBER 2024
  • TABLE 452 REVVITY, INC.: DEALS, JANUARY 2021-DECEMBER 2024
  • TABLE 453 SEEGENE INC.: COMPANY OVERVIEW
  • TABLE 454 SEEGENE INC.: PRODUCTS & SERVICES OFFERED
  • TABLE 455 SEEGENE INC.: PRODUCT LAUNCHES & APPROVALS, JANUARY 2021-DECEMBER 2024
  • TABLE 456 SEEGENE INC.: DEALS, JANUARY 2021-DECEMBER 2024
  • TABLE 457 SEEGENE INC.: EXPANSIONS, JANUARY 2021-DECEMBER 2024
  • TABLE 458 SEEGENE INC.: OTHER DEVELOPMENTS, JANUARY 2021-MARCH 2024
  • TABLE 459 NIHON KOHDEN CORPORATION: COMPANY OVERVIEW
  • TABLE 460 NIHON KOHDEN CORPORATION: PRODUCTS & SERVICES OFFERED
  • TABLE 461 VITALOGRAPH: COMPANY OVERVIEW
  • TABLE 462 VITALOGRAPH: PRODUCTS & SERVICES OFFERED
  • TABLE 463 VITALOGRAPH: PRODUCT & SERVICE LAUNCHES & APPROVALS, JANUARY 2021-DECEMBER 2024
  • TABLE 464 VITALOGRAPH: DEALS, JANUARY 2021-DECEMBER 2024
  • TABLE 465 SDI DIAGNOSTICS: COMPANY OVERVIEW
  • TABLE 466 SDI DIAGNOSTICS: PRODUCTS & SERVICES OFFERED
  • TABLE 467 RESMED INC.: COMPANY OVERVIEW
  • TABLE 468 RESMED INC.: PRODUCTS & SERVICES OFFERED
  • TABLE 469 RESMED INC.: DEALS, JANUARY 2021-DECEMBER 2024
  • TABLE 470 RESMED INC.: EXPANSIONS, JANUARY 2021-DECEMBER 2024
  • TABLE 471 RESMED INC.: OTHER DEVELOPMENTS, JANUARY 2021-DECEMBER 2024
  • TABLE 472 SIEMENS HEALTHINEERS AG: COMPANY OVERVIEW
  • TABLE 473 SIEMENS HEALTHINEERS AG: PRODUCTS & SERVICES OFFERED
  • TABLE 474 SIEMENS HEALTHINEERS AG: PRODUCT LAUNCHES, JANUARY 2021-DECEMBER 2024
  • TABLE 475 SIEMENS HEALTHINEERS AG: DEALS, JANUARY 2021-DECEMBER 2024
  • TABLE 476 SIEMENS HEALTHINEERS AG: EXPANSIONS, JANUARY 2021-DECEMBER 2024
  • TABLE 477 COSMED SRL: COMPANY OVERVIEW
  • TABLE 478 COSMED SRL: PRODUCTS & SERVICES OFFERED
  • TABLE 479 COSMED SRL: PRODUCT LAUNCHES, JANUARY 2021-DECEMBER 2024
  • TABLE 480 COSMED SRL: DEALS, JANUARY 2021-DECEMBER 2024
  • TABLE 481 HOLOGIC, INC.: COMPANY OVERVIEW
  • TABLE 482 HOLOGIC, INC.: PRODUCTS & SERVICES OFFERED
  • TABLE 483 HOLOGIC, INC.: PRODUCT LAUNCHES, JANUARY 2021-DECEMBER 2024
  • TABLE 484 HOLOGIC, INC.: DEALS, JANUARY 2021-DECEMBER 2024
  • TABLE 485 QIAGEN N.V.: COMPANY OVERVIEW
  • TABLE 486 QIAGEN N.V.: PRODUCTS & SERVICES OFFERED
  • TABLE 487 QIAGEN N.V.: PRODUCT LAUNCHES, JANUARY 2021-DECEMBER 2024
  • TABLE 488 QIAGEN N.V.: DEALS, JANUARY 2021-DECEMBER 2024
  • TABLE 489 QIAGEN N.V.: OTHER DEVELOPMENTS, JANUARY 2021-MARCH 2024

List of Figures

  • FIGURE 1 RESPIRATORY DIAGNOSTICS MARKET: MARKET & REGIONAL SPREAD
  • FIGURE 2 RESPIRATORY DIAGNOSTICS MARKET: YEARS CONSIDERED
  • FIGURE 3 RESEARCH DESIGN
  • FIGURE 4 RESPIRATORY DIAGNOSTICS MARKET: KEY PRIMARY SOURCES
  • FIGURE 5 RESPIRATORY DIAGNOSTICS MARKET: KEY DATA FROM PRIMARY SOURCES
  • FIGURE 6 RESPIRATORY DIAGNOSTICS MARKET: KEY INDUSTRY INSIGHTS
  • FIGURE 7 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY-SIDE AND DEMAND-SIDE PARTICIPANTS
  • FIGURE 8 BREAKDOWN OF PRIMARY INTERVIEWS (SUPPLY SIDE): BY COMPANY TYPE, DESIGNATION, AND REGION
  • FIGURE 9 BREAKDOWN OF PRIMARY INTERVIEWS (DEMAND SIDE): BY END USER, DESIGNATION, AND REGION
  • FIGURE 10 SUPPLY-SIDE MARKET SIZE ESTIMATION: REVENUE SHARE ANALYSIS
  • FIGURE 11 REVENUE SHARE ANALYSIS ILLUSTRATION: KONINKLIJKE PHILIPS N.V. (2023)
  • FIGURE 12 SUPPLY-SIDE ANALYSIS: RESPIRATORY DIAGNOSTICS MARKET (2023)
  • FIGURE 13 RESPIRATORY DIAGNOSTICS MARKET: TOP-DOWN APPROACH
  • FIGURE 14 CAGR PROJECTIONS FROM ANALYSIS OF DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
  • FIGURE 15 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS
  • FIGURE 16 RESPIRATORY DIAGNOSTICS MARKET: DATA TRIANGULATION METHODOLOGY
  • FIGURE 17 RESPIRATORY DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2024 VS. 2030 (USD MILLION)
  • FIGURE 18 RESPIRATORY DIAGNOSTICS MARKET, BY TEST TYPE, 2024 VS. 2030 (USD MILLION)
  • FIGURE 19 RESPIRATORY DIAGNOSTICS MARKET, BY DISEASE TYPE, 2024 VS. 2030 (USD MILLION)
  • FIGURE 20 RESPIRATORY DIAGNOSTICS MARKET, BY DIAGNOSIS TYPE, 2024 VS. 2030 (USD MILLION)
  • FIGURE 21 RESPIRATORY DIAGNOSTICS MARKET, BY END USER, 2024 VS. 2030 (USD MILLION)
  • FIGURE 22 GEOGRAPHIC SNAPSHOT OF RESPIRATORY DIAGNOSTICS MARKET
  • FIGURE 23 RISING PREVALENCE OF RESPIRATORY DISEASES TO PROPEL MARKET
  • FIGURE 24 INSTRUMENTS & DEVICES SEGMENT ACCOUNTED FOR LARGEST MARKET SHARE IN CHINA (2023)
  • FIGURE 25 ASIA PACIFIC TO REGISTER HIGHEST GROWTH RATE DURING FORECAST PERIOD
  • FIGURE 26 INDIA TO GROW AT HIGHEST GROWTH RATE DURING FORECAST PERIOD
  • FIGURE 27 RESPIRATORY DIAGNOSTICS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
  • FIGURE 28 CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) DALY FOR INDIVIDUALS IN AUSTRALIA, BY AGE (2023)
  • FIGURE 29 GLOBAL GERIATRIC POPULATION, BY REGION
  • FIGURE 30 RESPIRATORY DIAGNOSTICS MARKET: PORTER'S FIVE FORCES ANALYSIS
  • FIGURE 31 NUMBER OF PATENTS PUBLISHED, JANUARY 2014-DECEMBER 2024
  • FIGURE 32 TOP PATENT APPLICANTS AND OWNERS (COMPANIES/INSTITUTES) FOR RESPIRATORY DIAGNOSTICS DEVICES (JANUARY 2014- DECEMBER 2024)
  • FIGURE 33 TOP PATENT APPLICANTS, BY JURISDICTION, JANUARY 2014-DECEMBER 2024
  • FIGURE 34 AVERAGE SELLING PRICE OF SPIROMETERS, BY KEY PLAYER (2024)
  • FIGURE 35 AVERAGE SELLING PRICE OF PEAK FLOWMETERS, BY KEY PLAYER (2024)
  • FIGURE 36 RESPIRATORY DIAGNOSTICS MARKET: VALUE CHAIN ANALYSIS
  • FIGURE 37 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR RESPIRATORY DIAGNOSTIC DEVICES
  • FIGURE 38 KEY BUYING CRITERIA FOR RESPIRATORY DIAGNOSTIC DEVICES
  • FIGURE 39 RESPIRATORY DIAGNOSTICS MARKET: ADJACENT MARKETS
  • FIGURE 40 RESPIRATORY DIAGNOSTICS MARKET: ECOSYSTEM ANALYSIS
  • FIGURE 41 RESPIRATORY DIAGNOSTICS MARKET: SUPPLY CHAIN ANALYSIS
  • FIGURE 42 RESPIRATORY DIAGNOSTICS MARKET: TRENDS/DISRUPTIONS IMPACTING CUSTOMERS' BUSINESSES
  • FIGURE 43 RESPIRATORY DIAGNOSTICS MARKET: NUMBER OF DEALS, 2020-2024
  • FIGURE 44 RESPIRATORY DIAGNOSTICS MARKET: IMPACT OF AI/GEN AI
  • FIGURE 45 RESPIRATORY DIAGNOSTICS MARKET SNAPSHOT
  • FIGURE 46 NORTH AMERICA: RESPIRATORY DIAGNOSTICS MARKET SNAPSHOT
  • FIGURE 47 ASIA PACIFIC: RESPIRATORY DIAGNOSTICS MARKET SNAPSHOT
  • FIGURE 48 RESPIRATORY DIAGNOSTICS MARKET: REVENUE ANALYSIS OF KEY PLAYERS, 2019-2023
  • FIGURE 49 MARKET SHARE ANALYSIS OF KEY PLAYERS IN RESPIRATORY DIAGNOSTICS MARKET (2023)
  • FIGURE 50 RANKING OF KEY PLAYERS IN RESPIRATORY DIAGNOSTICS MARKET, 2023
  • FIGURE 51 RESPIRATORY DIAGNOSTICS MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2023
  • FIGURE 52 RESPIRATORY DIAGNOSTICS MARKET: COMPANY FOOTPRINT
  • FIGURE 53 RESPIRATORY DIAGNOSTICS MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2023
  • FIGURE 54 RESPIRATORY DIAGNOSTICS MARKET: BRAND/PRODUCT COMPARATIVE ANALYSIS
  • FIGURE 55 R&D EXPENDITURE OF KEY PLAYERS IN RESPIRATORY DIAGNOSTICS MARKET, 2022-2024
  • FIGURE 56 EV/EBITDA OF KEY VENDORS
  • FIGURE 57 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY VENDORS
  • FIGURE 58 KONINKLIJKE PHILIPS N.V.: COMPANY SNAPSHOT (2023)
  • FIGURE 59 BECTON, DICKINSON AND COMPANY: COMPANY SNAPSHOT (2024)
  • FIGURE 60 ABBOTT LABORATORIES: COMPANY SNAPSHOT (2023)
  • FIGURE 61 THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT (2023)
  • FIGURE 62 GE HEALTHCARE TECHNOLOGIES, INC.: COMPANY SNAPSHOT (2023)
  • FIGURE 63 BIO-RAD LABORATORIES, INC.: COMPANY SNAPSHOT (2023)
  • FIGURE 64 BIOMERIEUX: COMPANY SNAPSHOT (2023)
  • FIGURE 65 REVVITY, INC.: COMPANY SNAPSHOT (2023)
  • FIGURE 66 SEEGENE INC.: COMPANY SNAPSHOT (2023)
  • FIGURE 67 NIHON KOHDEN CORPORATION: COMPANY SNAPSHOT (2023)
  • FIGURE 68 RESMED INC.: COMPANY SNAPSHOT (2024)
  • FIGURE 69 SIEMENS HEALTHINEERS AG: COMPANY SNAPSHOT (2024)
  • FIGURE 70 HOLOGIC, INC.: COMPANY SNAPSHOT (2024)
  • FIGURE 71 QIAGEN N.V.: COMPANY SNAPSHOT (2023)